Janet McGill, MD
Enriched profileProfessor of Medicine, Division of Endocrinology, Metabolism & Lipid Research · Washington University in St. Louis
Janet McGill is Professor of Medicine, Division of Endocrinology, Metabolism & Lipid Research at Washington University in St. Louis. OpenAlex indexes 418 publications with 28,962 citations (h-index 86); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Janet McGill, MD, is Professor of Medicine, Division of Endocrinology, Metabolism & Lipid Research at Washington University in St. Louis (Washington University School of Medicine). The public record shows 418 publications with 28,962 citations (h-index 86), centered on Diabetes Treatment and Management, Diabetes Management and Research, Pancreatic function and diabetes. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 29 companies, 2 NIH-funded awards (1990–2007).
- Most recent indexed publication: 2026 · Diabetes, obesity & metabolism
- Top research focus: Diabetes Treatment and Management
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 29 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 234.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Participant
FDA Clinical Chemistry and Clinical Toxicology Devices Panel meeting on continuous glucose monitoring (Dexcom G5) review
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mobihealthnews.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Sponsor: COUR Pharmaceutical Development Company, Inc.
- Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
Sponsor: Washington University School of Medicine
Industry payments
Updated 16 Oct 2026
29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20256 payments
- Mannkind CorporationProgram year20259 payments
- PFIZER INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
63.1%Insulin Analog24.4%Lantus Solostar27%Humalog Kwikpen U-10011%Novolog10%Novolog Flexpen10%Humalog10%Basaglar Kwikpen U-1007%Tresiba Flextouch U-1006%Insulin Lispro Kwikpen U-1004%Insulin Lispro4%Insulin Lispro Junior Kwikpen3%Insulin Aspart Flexpen3%Humalog Kwikpen U-2002%Semglee (Yfgn) Pen2%Part D<11 patientsGLP-1 receptor agonist19.9%Trulicity37%Mounjaro35%Ozempic28%Part D≥27 patients+ 5 more classes in this area
Cardiovascular
26%Statin8.3%Atorvastatin Calcium63%Simvastatin19%Rosuvastatin Calcium18%Part D<11 patientsAngiotensin receptor blocker (ARB)5.4%Losartan Potassium64%Irbesartan-Hydrochlorothiazide21%Irbesartan15%Part D<11 patients+ 7 more classes in this area
Hormonal (systemic)
9.2%l-Thyroxine9.2%Levothyroxine Sodium74%Tirosint-Sol14%Synthroid13%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
2 NIH research awards on record, funded 1990–2007 per NIH RePORTER. The latest:
Congress activity
Updated 16 Oct 2026
25 congress contributions (2018–2026) across AACE, ADA, AMCP, ENDO per OpenAlex. The most recent:
- 1394-P: Impact of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Levels and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial
ADA Scientific Sessions
ADA2026Co-authorPoster - 1863-LB: The Confidence Trial—Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes
ADA Scientific Sessions
ADA2025Co-authorLate-breaking - 2007-LB: Dapagliflozin Alters TCA Cycle Activation during Insulin Withdrawal in T1D Patients
ADA Scientific Sessions
ADA2025Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Hypertension (Dallas, Tex.
Article2026 - Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
Journal of the American Society of Nephrology
Clinical Trial2026 - Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
Journal of the American Society of Nephrology
Article2026 - Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.
Nephrology, dialysis, transplantation
Review2026
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/janet-mcgill-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Janet-Mcgill-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/WashUMedEndo/status/1999235738144014549
- X / Twitter
x.com/WashUVFH/status/1998426110904692794
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Michigan State University College of Human Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endocrinology.wustl.edu ↗ - MA
Northern Michigan University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physicians.wustl.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endocrinology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endocrinology.wustl.edu ↗
- Residency and Chief Residency in Internal Medicine
William Beaumont Hospital (Royal Oak, MI)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endocrinology.wustl.edu ↗ - Fellowship in Endocrinology and Metabolism
Washington University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.washu.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endocrinology.wustl.edu ↗
- Former Director
Fellowship in Endocrinology, Diabetes and Metabolism, Washington University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physicians.wustl.edu ↗ - Principal Investigator
NIH-funded GRADE study (Washington University site)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wustl.edu ↗ - Former Principal Investigator
NIH-funded PERL study ("Preventing Early Renal Loss in Type 1 Diabetes")
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.wustl.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →professional.diabetes.org ↗
- Distinguished Clinician Award
Washington University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.washu.edu ↗ - Alumni Achievement Award
Washington University School of Medicine (HS '87)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.washu.edu ↗ - Endocrine Fellows' Teaching Award
Washington University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →endocrinology.wustl.edu ↗
Secondary affiliations
appointments beyond the home institution- Attending Physician
Barnes-Jewish Hospital, St. Louis, MO
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.wustl.edu ↗
Media & interviews
press, podcasts and appearances- "Finerenone Marks a Breakthrough for Kidney Protection in Type 1 Diabetes, with Janet McGill, MD, MA"
video interview, HCPLive
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗ - "Multifaceted Approach to Type 2 Diabetes Care"
Medscape/Reference video feature
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →reference.medscape.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Randall Bateman, MD
Washington University in St. Louis
Robert Carney, MD
Washington University in St. Louis
David Clifford, MD
Washington University in St. Louis
Eric Leuthardt, MD
Washington University in St. Louis
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH